Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
study ends around
Principal Investigator
by Rafael Bejar (ucsd)
Headshot of Rafael Bejar
Rafael Bejar

Description

Summary

This study aims to validate a novel, non-invasive diagnostic approach for blood and bone marrow malignancies using single-cell RNA sequencing of circulating hematopoietic stem and progenitor cells (cHSPCs) from peripheral blood. Building on prior work defining normal cHSPC profiles in healthy individuals, the study introduces a pipeline for identifying blood pathologies, with a focus on improving the diagnosis and subclassification of myelodysplastic syndromes (MDS). A multi-center clinical trial is proposed to evaluate the method's ability to predict bone marrow results in patients with cytopenia, potentially reducing reliance on bone marrow biopsies.

Official Title

Multi-Center Clinical Trial to Replace BM Analysis of Cytopenia by a Peripheral Blood Assay

Keywords

Cytopenia, PERIBLOOD

Eligibility

You can join if…

Open to people ages 18 years and up

  • Platelets < 150 × 109/L or
  • Absolute neutrophil count < 1.8 × 109/L or
  • Hemoglobin (Hgb) < 13 g/dL (males) and < 12 g/dL (female) and
  • For all genders, no evidence of Iron, folinic acid, or B12 deficiency
  • All subjects should be referred for BM analysis

You CAN'T join if...

  • Previous diagnosis of leukemia (AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy)
  • Lymphocytes>5000/ul
  • If patients are recruited after
  • Diagnosis of any disease related therapy 3 month prior to enrollment

Locations

  • University of California San Diego accepting new patients
    San Diego California 92093 United States
  • University of Miami accepting new patients
    Miami Florida 33146 United States

Lead Scientist at University of California Health

  • Rafael Bejar (ucsd)
    Our lab is focused on understanding the genetic changes that drive the development and progression of hematologic malignancies like acute myeloid leukemia and myelodysplastic syndromes. Our goal is to translate our discoveries into clinically meaningful improvements in how we care for patients with these disorders.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Weizmann Institute of Science
ID
NCT07081087
Study Type
Observational
Participants
Expecting 1500 study participants
Last Updated